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Abstract
Rationale Vortioxetine has reduced depressive symptoms in
adults with major depressive disorder (MDD) in multiple
clinical trials.
Objectives The aim of this study is to evaluate the efficacy,
safety, and tolerability of vortioxetine 15 and 20 mg vs place-
bo in adults with MDD.
Methods Patients were randomized 1:1:1:1 to vortioxetine
15 mg, vortioxetine 20 mg, duloxetine 60 mg (active refer-
ence), or placebo. The primary efficacy endpoint was mean
change in Montgomery–Åsberg Depression Rating Scale
(MADRS) total score at week 8 (MMRM). Safety/
tolerability assessments included physical examinations, vital
signs, laboratory evaluations, electrocardiograms, adverse
events (AEs), Columbia–Suicide Severity Rating Scale,
Arizona Sexual Experiences Scale, and Discontinuation–
Emergent Signs and Symptoms checklist.
Results Six hundred and fourteen patients were randomized.
Mean changes in MADRS scores were −12.83 (±0.834),
−14.30 (±0.890), −15.57 (±0.880), and −16.90 (±0.884) for
placebo, vortioxetine 15 mg (P=.224), vortioxetine 20 mg
(P=.023), and duloxetine 60 mg (P<.001) (P vs placebo),
respectively. AEs reported by ≥5 % of vortioxetine patients
included nausea, headache, diarrhea, dizziness, dry mouth,
constipation, vomiting, insomnia, fatigue, and upper respira-
tory infection. Treatment-emergent sexual dysfunction, sui-
cidal ideation or behavior, and discontinuation symptoms
were not significantly different between vortioxetine and
placebo.
Conclusions Vortioxetine 20 mg significantly reduced
MADRS total scores after 8 weeks of treatment. Both
vortioxetine doses were well tolerated.
Clinical trial registration ClinicalTrials.gov identifier
NCT01153009; www.clinicaltrials.gov/.
Keywords Antidepressant .MDD .Multimodal . ASEX .
Treatment-emergent sexual dysfunction
Introduction
Although numerous antidepressants are available for the treat-
ment of major depressive disorder (MDD), only about one
third of patients treated with an antidepressant achieve remis-
sion in the acute phase (Trivedi et al. 2006). Moreover, even
after multiple antidepressant therapies, over 30 % of patients
remain symptomatic in the short term (Rush et al. 2006).
Vortioxetine is a new antidepressant for the treatment of
MDD. The mechanism of action of vortioxetine is thought
to be related to a combination of two pharmacological modes
of action: direct modulation of receptor activity and inhibition
of the 5-HT (serotonin) transporter. In vitro studies indicate
that vortioxetine is a 5-HT3, 5-HT7, and 5-HT1D receptor
antagonist, a 5-HT1B receptor partial agonist, a 5-HT1A recep-
tor agonist, and an inhibitor of the 5-HT transporter (Bang-
Andersen et al. 2011; Sanchez et al. 2014). The precise con-
tribution of the individual targets to the observed pharmaco-
dynamic profile remains unclear. However, data from seroto-
nergic receptor and transporter occupancy studies, coupled
with neuronal firing and microdialysis studies in rats, suggest
that these targets interact in a complex fashion leading to
modulation of neurotransmission in several systems, includ-
ing serotonin, norepinephrine, dopamine, histamine, GABA,
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glutamate, and acetylcholine systems within the rat forebrain
(Bang-Andersen et al. 2011; Mørk et al. 2012; Pehrson et al.
2013; Sanchez et al. 2014). This multimodal pharmacological
activity is thought to be responsible for the antidepressant
effects of vortioxetine.
The efficacy of vortioxetine in reducing depressive symp-
toms has been demonstrated in patients with MDD in doses
from 5 to 20 mg/day (Alvarez et al. 2012; Katona et al. 2012;
Henigsberg et al. 2012; Baldwin et al. 2012a; Boulenger et al.
2012; Baldwin et al. 2012b; Jacobsen et al. 2013; Boulenger
et al. 2014; Jain et al. 2013; Mahableshwarkar et al. 2013b).
Overall, vortioxetine has been well tolerated across all trials.
The present phase 3 trial was conducted in the USA and
evaluated the efficacy, safety, and tolerability of vortioxetine
15 and 20 mg once daily doses vs placebo in MDD treatment.
A duloxetine 60-mg arm was included for trial validation; the
study was not powered for direct efficacy comparisons.
Methods
Study design
This 8-week, multicenter, randomized, double-blind, pla-
cebo-controlled, parallel-group, duloxetine-referenced,
phase 3 study was conducted at 58 sites in the USA.
Enrollment began in June 2010, and the study was com-
pleted in February 2012. The study was approved by
individual institutional review boards and conducted in
compliance with US Food and Drug Administration
(FDA) Code of Federal Regulations Part 56, the
International Conference on Harmonisation (ICH)
Harmonised Tripartite Guidelines for Good Clinical
Practice and the World Medical Association Declaration
of Helsinki. After providing signed informed consent, pa-
tients entered a 2- to 10-day screening period and, if
eligible, were randomized to receive study treatment.
Rater data monitoring
To control for the possible influence of rater differences, rater
assessments were supplemented by having each patient com-
plete a corresponding computerized Montgomery–Åsberg
Depression Rating Scale (MADRS) (Montgomery and
Asberg 1979) assessment (at screening, baseline, and weeks
1, 2, 4, 6, and 8) and Hamilton Anxiety Rating Scale (HAM-
A) (Hamilton 1959) assessment (baseline and weeks 2 and 8)
on the same dedicated study laptop computer.
Patients
Adult men and women (aged 18 to 75 years inclusive) were
included if they had a primary diagnosis of recurrent MDD as
defined by the Diagnostic and Statistical Manual of Mental
Disorders, 4th edition text revision with a reported duration of
current major depressive episode (MDE) ≥3 months. Patients
were required to have a MADRS total score ≥26 at screening
and baseline and a Clinical Global Impression–Severity (CGI-
S) (Guy 1976) total score ≥4.
Patients were not eligible for study participation if they met
any of the following exclusion criteria: treatment with any
investigational compound <30 days before screening or five
half-lives prior to screening; treatment with vortioxetine in a
previous clinical study; a lack of response to previous ade-
quate treatment with duloxetine for any MDE; symptoms
considered resistant to two or more antidepressant trials; any
concurrent psychiatric disorder other than MDD or prior his-
tory of psychiatric disorders such as manic or hypomanic
episode, schizophrenia, or substance abuse disorder; signifi-
cant risk of suicide in the opinion of the investigator or a score
of ≥5 on item 10 of the MADRS; or a history of neurological
disorders or medically unstable conditions (e.g., renal or he-
patic impairment; cardiovascular, pulmonary, or gastrointesti-
nal disorders; pain disorder, chronic fatigue syndrome, fibro-
myalgia, and obstructive sleep apnea). Additionally, patients
were prohibited from receiving formal cognitive or behavioral
therapy, systematic psychotherapy, or taking any medication
deemed to potentially affect the outcomes of the study. All
subjects were required to have a 2-week (or longer depending
on drug half-life) washout period for any psychoactive med-
ications prior to screening. After complete description of the
study to the subjects, written informed consent was obtained.
Study treatments
Eligible patients were randomized (1:1:1:1) to receive place-
bo, vortioxetine 15 mg, vortioxetine 20 mg, or duloxetine
60 mg once daily during the 8-week, double-blind treatment
period, using an interactive voice response system.
Randomization was stratified by patients’ sexual function
status (normal vs abnormal) as determined at baseline by the
Arizona Sexual Experiences (ASEX) scale (McGahuey et al.
2000). Abnormal sexual function was defined as having an
ASEX total score ≥19 or a score ≥5 on any item, or score ≥4
on any three items (Delgado et al. 2005). Following random-
ization, doses were up-titrated after the first week of the
double-blind period. Patients assigned to receive vortioxetine
15 or 20 mg received a 10-mg dose for the first week of the 8-
week study, and those assigned to receive duloxetine 60 mg
received a 30-mg dose for the first week.
Efficacy measures
The MADRS and CGI-S were assessed at screening, baseline,
and weeks 1, 2, 4, 6, and 8. HAM-Awas assessed at baseline
and weeks 1, 2, 4, 6, and 8; the Clinical Global Impressions–
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Improvement (CGI-I) scale (Guy 1976) at weeks 1, 2, 4, 6,
and 8; and the Sheehan Disability Scale (SDS) (Sheehan et al.
1996) at baseline and weeks 6 and 8.
Safety measures
Adverse events (AEs) were recorded at every study visit after
study medication was administered. They were coded by
system organ class and preferred term using the Medical
Dictionary for Regulatory Activities version 11.1. Additional
safety measures were assessed as follows: vital signs at weeks
0, 1, 2, 4, 6, and 8; weight, electrocardiogram and laboratory
values at weeks 0, 4, and 8; and physical examination findings
at week 8. Discontinuation symptoms were evaluated by the
Discontinuation–Emergent Signs and Symptoms (DESS)
scale during the 2-week discontinuation period. The
Columbia–Suicide Severity Rating Scale (C-SSRS) (Posner
et al. 2011) was measured at screening, baseline, and weeks 1,
2, 4, 6, and 8. ASEX was assessed at baseline and weeks 1, 2,
4, 6, and 8.
Statistical analysis
The safety set included all patients who received at least one
dose of study medication. The full analysis set comprised all
randomized patients who received at least one dose of study
drug and had at least one post-baseline value for the primary
efficacy assessment. Descriptive statistics and inferential sta-
tistics data analysis and tabulations were performed using
SAS System, version 9.1.3 (SAS Institute, Inc., Cary, NC)
on a Unix platform.
Statistical methods
The primary efficacy variable—change from baseline
MADRS total score at week 8—was analyzed using mixed
model for repeated measures (MMRM) analysis of covariance
(ANCOVA), with treatment, center, week, treatment-by-week
interaction, and baseline MADRS total score-by-week as
fixed effects, and a completely unstructured covariance ma-
trix. Based on missing data at random assumption, this anal-
ysis was performed using observed case (OC) data only. As
sensitivity analysis, the change from baseline inMADRS total
score after 8 weeks of treatment was also analyzed using
ANCOVA, with treatment and center as fixed factors, and
baseline MADRS total score as covariate, using last observa-
tion carried forward (LOCF) and OC methods. All statistical
tests were two-sided at a significance level of 5 % (except
where using corrections for multiplicity), comparing each of
the two vortioxetine doses with placebo. Ninety-five percent
confidence intervals are presented together with the estimated
P values.
Changes from baseline in HAM-A total score were ana-
lyzed by study visit using both MMRM and ANCOVA (by
both LOCF and OC) similar to the methods described above
for the primary variable where the baseline score was used as
the covariate adjustment in the MMRM and ANCOVA anal-
yses. A similar analysis was performed for CGI-S and CGI-I,
where the CGI-S baseline was used as the covariate adjust-
ment in the MMRM and ANCOVA analyses. The same was
the case for analysis of SDS total score and subscale change
from baseline, where the relevant baseline was used as the
covariate adjustment in the MMRM and ANCOVA analyses.
The treatment response, including MADRS response
(≥50 % decrease in MADRS), and MADRS remission
(MADRS ≤10) were analyzed at all time points by logistic
regression adjusting for baseline score and treatment using
both LOCF and OC methods.
To control for two-sided type I error, the primary efficacy
endpoint and key secondary endpoints were tested for each
dose in the following sequential order:
& Change from baseline in MADRS total score at week 8
(MMRM)
& MADRS responders at week 8 (LOCF)
& CGI-I at week 8 (MMRM)
& Change from baseline in MADRS total score at week 8 in
patients with baseline HAM-A ≥20 (MMRM)
& MADRS remission at week 8 (LOCF)
& Change from baseline in SDS total score at week 8
(MMRM)
As soon as the test of an endpoint was not significant at a
level of .025, the formal testing procedure was stopped.
Nominal P values with no adjustment for multiplicity were
reported for all comparisons between vortioxetine and placebo
for subsequent endpoints. The phrase “separation from place-
bo”was used to describe findings with nominal P values <.05.
Safety variables analysis
All safety assessments including AEs, clinical laboratory
evaluations, vital signs, 12-lead electrocardiogram results,
and physical examination results were summarized with de-
scriptive statistics, where appropriate. The number of patients
with positive reports on the C-SSRS at baseline and during
treatment was summarized using descriptive statistics. A re-
port was considered positive if the patient reported any of the
following suicidal ideation or behavior (SIB) during treat-
ment: active suicidal ideation with some intent to act without
specific plan, active suicidal ideation with specific plan and
intent, interrupted/aborted suicide attempt, preparatory
acts/behavior, actual attempt, or completed suicide.
The primary ASEX analysis assessed the number of pa-
tients who were normal at baseline and developed sexual
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dysfunction (ASEX total score ≥19, or score ≥5 on any item,
or score ≥4 on any three items) anytime during the study
period. Change from baseline in ASEX total score and indi-
vidual items were summarized and analyzed at all time points
based on MMRM with treatment, center, week, treatment-by-
week interaction, and baseline ASEX total score-by-week as
fixed effects.
In patients who completed the 8-week, double-blind peri-
od, potential discontinuation symptoms were assessed using
the DESS scale, which was administered during a single-blind
2-week period (weeks 9 and 10) following an abrupt discon-
tinuation of vortioxetine treatment. Patients in the duloxetine
60-mg group had their dose tapered to 30mg for the first week
of the discontinuation period.
Comparisons between the different doses of vortioxetine
and placebo were performed using an ANCOVA model with
treatment and center as factors and the score at week 8 as a
covariate. Descriptive statistics were reported for AEs, vital




Of the 1141 patients screened, 614 (54 %) were randomized
(placebo, n=161; vortioxetine 15 mg, n=147; vortioxetine
20 mg, n=154; and duloxetine 60 mg, n=152) (Fig. 1).
Demographics and baseline characteristics
Demographics and baseline clinical characteristics were bal-
anced across treatment groups (Table 1). In the overall popu-
lation, 26 % were male, 77 % were White, the mean age was
42.9 years, and the mean body mass index was 31.2 kg/m2.
The mean duration of the current MDE was 41.2, 38.4, 37.7,
and 44.0 weeks in the placebo, vortioxetine 15-mg,
vortioxetine 20-mg, and duloxetine 60-mg groups, respective-
ly. Most of the patients (69.4 % overall) had one to three
previousMDEs upon entrance into the study, and the majority
of patients had been treated for MDEs during the current or
previous episode, with 90.4 % overall having received
pharmacotherapy.
Efficacy analyses
In the primary efficacy analysis, vortioxetine 20 mg was
statistically significantly better than placebo (−15.57±0.880
vs −12.83±0.834; P=.023) in reducing the MADRS total
score at week 8, with a least-squares mean difference from
placebo of −2.8 points (Table 2; Fig. 2). Vortioxetine 15 mg
was not significantly different from placebo at week 8 (−14.30
±0.890 vs –12.83±0.834; P=.224). Duloxetine 60 mg sepa-
rated from placebo (−16.90±0.884 vs −12.83±0.834;
P<.001) on the primary endpoint, confirming assay sensitiv-
ity. In the ANCOVA analyses based on LOCF andOC, neither
vortioxetine dose separated from placebo.
As shown in Table 2, the key secondary efficacy endpoints
did not separate from placebo (P> .050) with either
vortioxetine dose. The mean changes from baseline in SDS
total score (MMRM) were numerically larger in the
vortioxetine treatment groups compared with placebo; how-
ever, neither dose separated from placebo statistically.
Safety variables
The most common AEs reported in ≥5 % of patients in
either of the vortioxetine treatment groups were nausea,
headache, diarrhea, dizziness, dry mouth, constipation,
vomiting, insomnia, fatigue, nasopharyngitis, and upper
respiratory infection (Table 3). Discontinuation due to
AEs occurred in 4 (2.5 %) patients in the placebo group,
14 (9.5 %) in the vortioxetine 15-mg group, 14 (9.1 %) in
the vortioxetine 20-mg group, and 10 (6.6 %) in the
duloxetine 60-mg group (Fig. 1). The most common AE
leading to study discontinuation (≥2 % of patients) in the
vortioxetine treatment groups was nausea.
Two serious AEs (a stress fracture and suicidal ideation)
occurred in the vortioxetine 15-mg group during the study.
The patient with suicidal ideation recovered from the event
and continued in the study. There were no deaths among the
study participants.
Changes in serum chemistry, hematology, vital signs, and
electrocardiogram parameters were distributed evenly across
vortioxetine and placebo groups; no discernible patterns of
concern were noted for any of the treatment groups.
C-SSRS At the baseline (lifetime) assessment, the incidence
of patients with positive C-SSRS reports was similar across
the placebo (23.3 %), vortioxetine 15-mg (17.0 %),
vortioxetine 20-mg (27.3 %), and duloxetine 60-mg
(21.3 %) groups. During the study, one patient in the
vortioxetine 15-mg group and one patient in the vortioxetine
20-mg group had active suicidal ideation compared with no
patients in the placebo group and two patients in the
duloxetine group; no suicidal behavior-related events were
reported during the study.
ASEX Approximately one third of patients in each treatment
group were without sexual dysfunction at baseline. Of the 58
patients without sexual dysfunction at baseline in the placebo
group, 21 patients (36.2 %) developed sexual dysfunction
during the study. Of the 45 patients without sexual dysfunc-
tion at baseline in the vortioxetine 15-mg group, 16 patients
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Table 1 Demographics and other baseline characteristics
Placebo (n=161) Vortioxetine 15 mg (n=147) Vortioxetine 20 mg (n=154) Duloxetine 60 mg (n=152)
Age, mean (±SD) (years) 42.4 (±12.55) 43.1 (±12.28) 42.8 (±12.40) 43.4 (±12.24)
Range 20–73 21–75 19–72 19–72
Female, n (%) 116 (72.0) 104 (70.7) 114 (74.0) 119 (78.3)
Race, n (%)
White 122 (75.8) 114 (77.6) 115 (74.7) 119 (78.3)
Black 37 (23.0) 31 (21.1) 36 (23.4) 32 (21.1)
Asian 1 (0.6) 2 (1.4) 3 (1.9) 1(0.7)
Native American/Alaskan native 1 (0.6) 0 0 0
BMI, mean (±SD) (kg/m2) 31.1 (±7.88) 31.3 (±7.48) 30.9 (±7.63) 31.5 (±8.45)
MADRS total score, mean (±SD) 31.6 (±4.18) 31.9 (±4.08) 32.0 (±4.36) 32.9 (±4.39)
HAM-A total score, mean (±SD) 17.0 (±5.12) 17.5 (±5.28) 17.8 (±5.42) 18.4 (±5.81)
CGI-S total score, mean (±SD) 4.6 (±0.58) 4.5 (±0.55) 4.5 (±0.60) 4.5 (±0.60)
BMI body mass index, CGI-S Clinical Global Impression–Severity, HAM-AHamilton Anxiety Rating Scale,MADRSMontgomery–Åsberg Depression
Rating Scale, SD standard deviation
Screened (N=1141)
Screen failures (n=527)
♦ Did not meet inclusion criteria (n=104)
♦ Met exclusion criteria (n=363)
♦ Withdrawal of consent (n=31)
♦ Lost to follow-up (n=16)
♦ Pretreatment adverse event (n=5)




Full analysis setb (n=153)
Per-protocol setc (n=150)
Prematurely discontinued (n=32)
♦ Adverse Event (n=4)
♦ Lack of efficacy (n=9)
♦ Noncompliance (n=1)
♦ Protocol deviation (n=4)
♦ Withdrawal of consent (n=5)




♦ Adverse Event (n=14)
♦ Lack of efficacy (n=0)
♦ Noncompliance (n=3)
♦ Protocol deviation (n=3)
♦ Withdrawal of consent (n=5)
♦ Lost to follow-up (n=8)
♦ Other (n=1)
Vortioxetine 15 mg (n=147)
Safety seta (n=147)
Full analysis setb (n=145)
Per-protocol setc (n=127)
Safety seta (n=154)
Full analysis setb (n=147)
Per-protocol setc (n=135)
Prematurely discontinued (n=41)
♦ Adverse Event (n=14)
♦ Lack of efficacy (n=2)
♦ Noncompliance (n=4)
♦ Protocol deviation (n=3)
♦ Withdrawal of consent (n=4)
♦ Lost to follow-up (n=11)
♦ Other (n=3)
Vortioxetine 20 mg (n=154)
Prematurely discontinued (n=37)
♦ Adverse Event (n=10)
♦ Lack of efficacy (n=1)
♦ Noncompliance (n=1)
♦ Protocol deviation (n=2)
♦ Withdrawal of consent (n=6)
♦ Lost to follow-up (n=15)
♦ Other (n=2)
Duloxetine 60 mg (n=152)
Safety seta (n=150)
Full analysis setb (n=146)
Per-protocol setc (n=134)
Fig. 1 Patient disposition.aAll randomized patients who received ≥1
dose of double-blind study medication; bAll randomized patients who
received ≥1 dose of double-blind study medication and had ≥1 valid post-
baseline efficacy assessment; cAll patients in the full analysis set who had
no major protocol violations
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(35.6 %) developed sexual dysfunction during the study; and
of the 45 patients without sexual dysfunction at baseline in the
vortioxetine 20-mg group, 16 patients (35.6 %) developed
sexual dysfunction during the study (Table 4). In the overall
study population, there was no statistically significant differ-
ence between the vortioxetine treatment groups and placebo
regarding the incidence of sexual dysfunction during the
study. The vortioxetine 15- and 20-mg groups had a 0.7 %
lower rate of sexual dysfunction compared with placebo and a
17.6 % lower rate of sexual dysfunction compared with
duloxetine.
When the ASEX scores were analyzed by sex, there were
also no differences from placebo for either male or female
patients at week 8 in the vortioxetine treatment groups.
DESS Abrupt treatment discontinuation with vortioxetine
15 and 20 mg resulted in no statistically significant differ-
ences in DESS total scores compared with placebo at week
9 (placebo, 1.1; vortioxetine 15 mg, 1.8; vortioxetine
20 mg, 1.8) or week 10 (placebo, 1.7; vortioxetine 15 mg,
2.5; vortioxetine 20 mg, 1.6) of the 2-week, single-blind
discontinuation period. Following dose-tapering,
Table 2 Primary and key secondary endpoints
Variable Placebo Vortioxetine 15 mg Vortioxetine 20 mg Duloxetine 60 mg








Difference from placebo, LS mean (±SE) −1.48 (±1.214) −2.75 (±1.206) −4.07 (±1.214)
P value .224b .023 <.001
95 % CI for difference (−3.86, 0.91) (−5.12, −0.38) (−6.46, −1.69)








Difference from placebo (%) 4.9 5.0 15.6
Odds ratio vs placebo 1.249 1.257 1.991
P value .348 .332b .004
95 % CI for odds ratio (0.786, 1.984) (0.792, 1.994) (1.250, 3.171)








Difference from placebo, LS mean (±SE) −0.12 (±0.140) −0.19 (±0.139) −0.34 (±0.139)
P value .400 .177 .014
95 % CI for difference (−0.39, 0.16) (−0.46, 0.08) (−0.61, −0.07)








Difference from placebo, LS mean (±SE) 0.93 (±2.286) −0.62 (±2.416) −4.05 (±2.278)
P value .684 .797 .078
95 % CI for difference (−3.56, 5.45) (−5.40, 4.15) (−8.54, 0.45)








Difference from placebo (%) 0.1 2.5 −0.8
Odds ratio vs placebo 1.053 1.192 1.098
P value .845 .503 .728
95 % CI for odds ratio (0.625, 1.775) (0.713, 1.994) (0.648, 1.860)








Difference from placebo, LS mean (±SE) −0.05 (±1.111) −0.88 (±1.103) −1.99 (±1.123)
P value .962 .427 .078
95 % CI for difference (−2.24, 2.13) (−3.05, 1.29) (−4.19, 0.22)
CGI-I Clinical Global Impression–Improvement, HAM-A Hamilton Anxiety Rating Scale, LS least-squares,MADRSMontgomery–Åsberg Depression
Rating Scale, SDS Sheehan Disability Scale, SE standard error
a Primary efficacy analysis
b The testing strategy stopped at this step for all subsequent endpoints with that dose; all subsequent P values are nominal
c Logistic regression analyses for response and remission (last observation carried forward); values are percentage point differences from placebo
d Treatment difference from placebo in mean CGI-I score at week 8
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differences from placebo in DESS total scores in the
duloxetine group (week 9, 1.5; week 10, 2.7) were not
statistically significant.
Discussion
Vortioxetine 20-mg treatment was statistically significantly
superior to placebo on the primary efficacy analysis and
demonstrated continual improvement over the 8-week study.
Change from baseline in MADRS total score in the
vortioxetine 15-mg group demonstrated improvement over
time and was numerically greater than placebo but not statis-
tically significant at week 8. The active reference, duloxetine
60 mg, separated from placebo, confirming assay sensitivity.
Neither vortioxetine dose separated from placebo on any of
the key secondary efficacy endpoints. Although some im-
provements in SDS total scores were apparent in the
vortioxetine 20-mg and duloxetine 60-mg groups, the differ-
ences from placebo did not reach statistical significance.
Overall, in the MDD development program, vortioxetine has
been studied at doses from 5 to 20 mg. Efficacy has been
replicated at the 5-, 10-, and 20-mg doses in adults, and a
dedicated elderly study demonstrated efficacy at 5 mg
(Alvarez et al. 2012; Katona et al. 2012; Henigsberg et al.
2012; Baldwin et al. 2012a; Baldwin et al. 2012b; Jacobsen
et al. 2013; Boulenger et al. 2014). Vortioxetine 20 mg has
been shown to be significantly superior to placebo onmultiple
depression endpoints (MADRS total score, response rate,
CGI-I, SDS, and MADRS in patients with high baseline
HAM-A) after 8 weeks of treatment in two other studies,
one conducted in the USA and the other conducted outside
of the USA (Jacobsen et al. 2013; Boulenger et al. 2014).
Additionally, there has been a tendency across studies to see
increasing efficacy at higher doses (Alvarez et al. 2012;
Henigsberg et al. 2012; Baldwin et al. 2012b; Jacobsen et al.
2013; Boulenger et al. 2014). The reasons for failure of the
vortioxetine 15-mg dose to separate from placebo in the
current study remain unclear as this dose did demonstrate
statistically significant improvement over placebo in a previ-
ous study conducted outside of the USA (Boulenger et al.
2014). However, another study evaluating vortioxetine 10 and
15 mg conducted in the USA failed (Mahableshwarkar et al.
2013a), so there has been some inconsistency in efficacy
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Fig. 2 Least-squares change
from baseline in Montgomery–
Åsberg Depression Rating Scale
total score by visit (full analysis
set; mixed model for repeated
measures). *Nominal P<.050;
**Nominal P<.010; ***Nominal
P<.001 vs placebo; †P<.025
Table 3 TEAEs experienced by ≥5 % of patients











Any TEAE 112 (70.4) 108 (73.5) 125 (81.2) 122 (81.3)
Nausea 18 (11.3) 52 (35.4) 51 (33.1) 55 (36.7)
Dry mouth 16 (10.1) 14 (9.5) 22 (14.3) 26 (17.3)
Headache 21 (13.2) 26 (17.7) 20 (13.0) 28 (18.7)
Dizziness 5 (3.1) 15 (10.3) 20 (13.0) 24 (16.0)
Constipation 10 (6.3) 8 (5.4) 14 (9.1) 18 (12.0)
Vomiting 1 (0.6) 7 (4.8) 13 (8.4) 12 (8.0)
Insomnia 8 (5.0) 5 (3.4) 13 (8.4) 14 (9.3)
Diarrhea 10 (6.3) 22 (15.0) 12 (7.8) 19 (12.7)
Fatigue 4 (2.5) 7 (4.8) 8 (5.2) 17 (11.3)
Nasopharyngitis 10 (6.3) 6 (4.1) 9 (5.8) 5 (5.3)
Upper respiratory
tract infection
11 (6.9) 5 (3.4) 8 (5.2) 7 (4.7)
ATEAEwas defined as an adverse event with an onset that occurred after
receiving study drug and within 30 days after receiving the last dose of
study drug
TEAE treatment–emergent adverse event
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population differences in the USA that require higher doses
(i.e., greater heterogeneity of the population, higher mean
BMI) or may relate to methodological issues, including as-
pects of study design and conduct (i.e., issues with identifying
appropriate patients, large multi-site trials, multiple raters) that
have been previously proposed as possible reasons for nega-
tive clinical trials in MDD (Bridge et al., 2009; Brunoni et al.,
2009; Khan et al., 2010; Mundt et al., 2007).
Drugs that act at multiple targets are hypothesized to have a
higher potential for side effects. However, vortioxetine was
consistently well tolerated across different study populations
when measured by various objective scales in addition to
spontaneously reported AEs, as was the case in this study.
Patients in this trial received the two highest vortioxetine
doses studied to date. Even at these doses, AE discontinuation
rates were generally low. Nausea was the most common dose-
related AE resulting in study withdrawal. Most AEs were of
mild to moderate intensity. The prevalence of nausea was
transient and highest during the first week of treatment. SIB
was prospectively monitored using the C-SSRS scores in all
vortioxetine clinical trials, and there was no evidence to sug-
gest that vortioxetine is associated with an increase in SIB in
adults with MDD. Abrupt treatment discontinuation of
vortioxetine 15 and 20 mg resulted in no statistically signifi-
cant differences in the incidence of DESS compared with
placebo.
Sexual dysfunction, a frequent side effect of drugs with
serotonin reuptake inhibitor properties, is a common reason
for treatment discontinuation. A meta-analysis of treatment-
emergent sexual dysfunction (TESD) reported that TESD
incidence ranged from 26 to 80% depending on the treatment.
Atypical antidepressants such as bupropion, mirtazapine, and
nefazodone are less likely to cause TESD (Serretti and Chiesa
2009). In this study, the impact of vortioxetine on sexual
dysfunction was assessed with ASEX, a validated patient-
reported assessment tool (McGahuey et al. 2000) using
duloxetine as an active control. As mentioned previously,
the primary ASEX analysis assessed the number of patients
who were normal at baseline and developed sexual dysfunc-
tion during the study. In this study, 32 % of patients had no
sexual dysfunction at baseline. Approximately one third
(36 %) of these patients in the placebo and vortioxetine 15-
and 20-mg groups reported TESD at some point during the
trial. In the duloxetine treatment group, approximately one
half (53 %) developed TESD. These results are consistent
with vortioxetine having a favorable tolerability profile and
a low risk of TESD. In sum, vortioxetine 20 mg/day signifi-
cantly reduced MADRS total score after 8 weeks of treatment
compared with placebo. Vortioxetine treatment groups were
comparable to placebo in ASEX, C-SSRS, and DESS scores.
Overall, the vortioxetine safety and tolerability profile was
favorable.
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